Curing HCV in Incarcerated Patients

Status unconfirmed · Phase 4

Conditions studied: Hepatitis C, Chronic

In brief

Curing HCV in Incarcerated Patients (CHIP) is a 1-year demonstration project that will assess the feasibility of a HCV treatment program in the San Francisco City \& County Jail. The Jail Health Services will treat 100 patients using the FDA approved combination treatment, sofosbuvir/velpatasvir, Epclusa® and will continue their treatment during incarceration and after their release (if applicable).

Key facts

Study ID

NCT03018353

Run by

San Francisco Department of Public Health

People needed

100

Starts

2017-03-05

Expected to finish

2018-06-04

Last updated by the study team

2017-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• a detectable HCV viral load
• no medical contraindications to treatment, including limited life expectancy of less than 12-months due to non-liver related comorbid conditions or renal failure with creatinine clearance of < 30 mL/min.
• Must start HCV treatment while detained
• HIV positive or negative status
• HBV positive or negative status
• treatment-naïve or experienced
• with or without cirrhosis

You may not qualify if…

• a limited life expectancy of less than 12-months due to non-liver related comorbid conditions
• current or history of decompensated cirrhosis, defined as presence of ascites, hepatic encephalopathy, or variceal bleeding within the past 6 months.
• severe renal impairment defined as creatinine clearance of < 30 mL/min or end stage renal disease (ESRD) on hemodialysis
• pregnant

Where it is running

• Jail Health Services — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.